nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP2A6—Prednisolone—multiple sclerosis	0.0678	0.107	CbGbCtD
Cyclophosphamide—CYP2D6—Fingolimod—multiple sclerosis	0.0515	0.0812	CbGbCtD
Cyclophosphamide—CYP2A6—Dexamethasone—multiple sclerosis	0.0399	0.0629	CbGbCtD
Cyclophosphamide—ABCB1—Methylprednisolone—multiple sclerosis	0.0352	0.0555	CbGbCtD
Cyclophosphamide—CYP3A4—Fingolimod—multiple sclerosis	0.0328	0.0516	CbGbCtD
Cyclophosphamide—CYP3A7—Dexamethasone—multiple sclerosis	0.0273	0.043	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0273	0.043	CbGbCtD
Cyclophosphamide—CYP2C19—Prednisone—multiple sclerosis	0.0265	0.0417	CbGbCtD
Cyclophosphamide—CYP2B6—Dexamethasone—multiple sclerosis	0.026	0.041	CbGbCtD
Cyclophosphamide—ABCB1—Mitoxantrone—multiple sclerosis	0.0257	0.0405	CbGbCtD
Cyclophosphamide—ABCB1—Betamethasone—multiple sclerosis	0.0229	0.0361	CbGbCtD
Cyclophosphamide—ABCB1—Prednisolone—multiple sclerosis	0.0226	0.0356	CbGbCtD
Cyclophosphamide—ABCB1—Prednisone—multiple sclerosis	0.0214	0.0337	CbGbCtD
Cyclophosphamide—CYP3A4—Methylprednisolone—multiple sclerosis	0.0211	0.0333	CbGbCtD
Cyclophosphamide—CYP3A5—Dexamethasone—multiple sclerosis	0.0205	0.0323	CbGbCtD
Cyclophosphamide—CYP2C8—Dexamethasone—multiple sclerosis	0.0197	0.031	CbGbCtD
Cyclophosphamide—CYP2C19—Dexamethasone—multiple sclerosis	0.0165	0.026	CbGbCtD
Cyclophosphamide—CYP3A4—Triamcinolone—multiple sclerosis	0.016	0.0252	CbGbCtD
Cyclophosphamide—CYP3A4—Mitoxantrone—multiple sclerosis	0.0154	0.0243	CbGbCtD
Cyclophosphamide—CYP2C9—Dexamethasone—multiple sclerosis	0.0137	0.0216	CbGbCtD
Cyclophosphamide—CYP3A4—Betamethasone—multiple sclerosis	0.0137	0.0216	CbGbCtD
Cyclophosphamide—CYP3A4—Prednisolone—multiple sclerosis	0.0135	0.0213	CbGbCtD
Cyclophosphamide—ABCB1—Dexamethasone—multiple sclerosis	0.0133	0.021	CbGbCtD
Cyclophosphamide—CYP3A4—Prednisone—multiple sclerosis	0.0128	0.0202	CbGbCtD
Cyclophosphamide—CYP2D6—Dexamethasone—multiple sclerosis	0.0126	0.0198	CbGbCtD
Cyclophosphamide—ABCB1—Methotrexate—multiple sclerosis	0.0107	0.0169	CbGbCtD
Cyclophosphamide—CYP3A4—Dexamethasone—multiple sclerosis	0.00799	0.0126	CbGbCtD
Cyclophosphamide—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000287	0.0064	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000287	0.0064	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000284	0.00635	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000284	0.00635	CbGpPWpGaD
Cyclophosphamide—ABCB1—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000277	0.00618	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000265	0.00592	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000256	0.00572	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000256	0.00572	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Biological oxidations—CYP24A1—multiple sclerosis	0.000244	0.00544	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Biological oxidations—CYP27B1—multiple sclerosis	0.000244	0.00544	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00024	0.00536	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00024	0.00536	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000236	0.00526	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000236	0.00526	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000234	0.00522	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000234	0.00522	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Biological oxidations—CYP24A1—multiple sclerosis	0.000223	0.00498	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Biological oxidations—CYP27B1—multiple sclerosis	0.000223	0.00498	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000216	0.00481	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—C4A—multiple sclerosis	0.000211	0.0047	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000191	0.00427	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00019	0.00424	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00019	0.00424	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000188	0.00419	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000188	0.00419	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Biological oxidations—CYP27B1—multiple sclerosis	0.00018	0.00402	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Biological oxidations—CYP24A1—multiple sclerosis	0.00018	0.00402	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000178	0.00397	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000178	0.00397	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.000176	0.00393	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.000176	0.00393	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000174	0.00388	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000174	0.00388	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—IL12A—multiple sclerosis	0.000172	0.00383	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—CXCL13—multiple sclerosis	0.000172	0.00383	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000171	0.00381	CbGpPWpGaD
Cyclophosphamide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000159	0.00355	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.000156	0.00349	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000155	0.00346	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000154	0.00344	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000154	0.00344	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Biological oxidations—CYP24A1—multiple sclerosis	0.000152	0.0034	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Biological oxidations—CYP27B1—multiple sclerosis	0.000152	0.0034	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00015	0.00336	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00015	0.00336	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000149	0.00332	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000148	0.00331	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	0.000147	0.00329	CbGpPWpGaD
Cyclophosphamide—Erythema—Dexamethasone—multiple sclerosis	0.000137	0.000426	CcSEcCtD
Cyclophosphamide—Erythema—Betamethasone—multiple sclerosis	0.000137	0.000426	CcSEcCtD
Cyclophosphamide—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000136	0.00304	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.000136	0.00304	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.000136	0.00304	CbGpPWpGaD
Cyclophosphamide—Malaise—Triamcinolone—multiple sclerosis	0.000136	0.000423	CcSEcCtD
Cyclophosphamide—Pancytopenia—Methotrexate—multiple sclerosis	0.000135	0.000423	CcSEcCtD
Cyclophosphamide—Malaise—Methylprednisolone—multiple sclerosis	0.000135	0.000422	CcSEcCtD
Cyclophosphamide—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000134	0.003	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000134	0.003	CbGpPWpGaD
Cyclophosphamide—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000134	0.000418	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	0.000134	0.00298	CbGpPWpGaD
Cyclophosphamide—Oedema—Prednisolone—multiple sclerosis	0.000134	0.000417	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000134	0.000417	CcSEcCtD
Cyclophosphamide—Dizziness—Azathioprine—multiple sclerosis	0.000133	0.000415	CcSEcCtD
Cyclophosphamide—Shock—Prednisolone—multiple sclerosis	0.000131	0.00041	CcSEcCtD
Cyclophosphamide—Cough—Triamcinolone—multiple sclerosis	0.000131	0.00041	CcSEcCtD
Cyclophosphamide—Convulsion—Triamcinolone—multiple sclerosis	0.00013	0.000407	CcSEcCtD
Cyclophosphamide—Tachycardia—Prednisolone—multiple sclerosis	0.00013	0.000407	CcSEcCtD
Cyclophosphamide—Convulsion—Methylprednisolone—multiple sclerosis	0.00013	0.000406	CcSEcCtD
Cyclophosphamide—Hypertension—Triamcinolone—multiple sclerosis	0.00013	0.000405	CcSEcCtD
Cyclophosphamide—Hypertension—Methylprednisolone—multiple sclerosis	0.00013	0.000404	CcSEcCtD
Cyclophosphamide—Urticaria—Mitoxantrone—multiple sclerosis	0.000129	0.000403	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000129	0.000403	CcSEcCtD
Cyclophosphamide—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000129	0.000401	CcSEcCtD
Cyclophosphamide—Myalgia—Triamcinolone—multiple sclerosis	0.000128	0.0004	CcSEcCtD
Cyclophosphamide—Vomiting—Azathioprine—multiple sclerosis	0.000128	0.000399	CcSEcCtD
Cyclophosphamide—Pneumonia—Methotrexate—multiple sclerosis	0.000128	0.000399	CcSEcCtD
Cyclophosphamide—Myalgia—Methylprednisolone—multiple sclerosis	0.000128	0.000399	CcSEcCtD
Cyclophosphamide—Arthralgia—Methylprednisolone—multiple sclerosis	0.000128	0.000399	CcSEcCtD
Cyclophosphamide—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000127	0.00284	CbGpPWpGaD
Cyclophosphamide—Rash—Azathioprine—multiple sclerosis	0.000127	0.000396	CcSEcCtD
Cyclophosphamide—Dermatitis—Azathioprine—multiple sclerosis	0.000127	0.000396	CcSEcCtD
Cyclophosphamide—Flushing—Prednisone—multiple sclerosis	0.000127	0.000395	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000127	0.000395	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000127	0.000395	CcSEcCtD
Cyclophosphamide—Discomfort—Triamcinolone—multiple sclerosis	0.000127	0.000395	CcSEcCtD
Cyclophosphamide—Discomfort—Methylprednisolone—multiple sclerosis	0.000126	0.000394	CcSEcCtD
Cyclophosphamide—Headache—Azathioprine—multiple sclerosis	0.000126	0.000394	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000126	0.000393	CcSEcCtD
Cyclophosphamide—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.000125	0.00279	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.000125	0.00279	CbGpPWpGaD
Cyclophosphamide—Renal failure—Methotrexate—multiple sclerosis	0.000125	0.00039	CcSEcCtD
Cyclophosphamide—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000124	0.00277	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000124	0.00277	CbGpPWpGaD
Cyclophosphamide—Stomatitis—Methotrexate—multiple sclerosis	0.000124	0.000387	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Methotrexate—multiple sclerosis	0.000124	0.000386	CcSEcCtD
Cyclophosphamide—Confusional state—Methylprednisolone—multiple sclerosis	0.000124	0.000385	CcSEcCtD
Cyclophosphamide—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000123	0.00276	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000123	0.00276	CbGpPWpGaD
Cyclophosphamide—Malaise—Dexamethasone—multiple sclerosis	0.000123	0.000384	CcSEcCtD
Cyclophosphamide—Malaise—Betamethasone—multiple sclerosis	0.000123	0.000384	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000123	0.000383	CcSEcCtD
Cyclophosphamide—Oedema—Triamcinolone—multiple sclerosis	0.000123	0.000383	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000123	0.000382	CcSEcCtD
Cyclophosphamide—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000122	0.00273	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000122	0.00273	CbGpPWpGaD
Cyclophosphamide—Arrhythmia—Prednisone—multiple sclerosis	0.000122	0.000381	CcSEcCtD
Cyclophosphamide—Infection—Triamcinolone—multiple sclerosis	0.000122	0.000381	CcSEcCtD
Cyclophosphamide—Sweating—Methotrexate—multiple sclerosis	0.000122	0.00038	CcSEcCtD
Cyclophosphamide—Infection—Methylprednisolone—multiple sclerosis	0.000122	0.00038	CcSEcCtD
Cyclophosphamide—Haematuria—Methotrexate—multiple sclerosis	0.000121	0.000378	CcSEcCtD
Cyclophosphamide—Shock—Triamcinolone—multiple sclerosis	0.000121	0.000377	CcSEcCtD
Cyclophosphamide—Alopecia—Prednisone—multiple sclerosis	0.000121	0.000377	CcSEcCtD
Cyclophosphamide—Shock—Methylprednisolone—multiple sclerosis	0.000121	0.000376	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00012	0.000374	CcSEcCtD
Cyclophosphamide—Paraesthesia—Prednisolone—multiple sclerosis	0.00012	0.000374	CcSEcCtD
Cyclophosphamide—Tachycardia—Triamcinolone—multiple sclerosis	0.00012	0.000374	CcSEcCtD
Cyclophosphamide—Nausea—Azathioprine—multiple sclerosis	0.00012	0.000373	CcSEcCtD
Cyclophosphamide—Tachycardia—Methylprednisolone—multiple sclerosis	0.00012	0.000373	CcSEcCtD
Cyclophosphamide—Erythema—Prednisone—multiple sclerosis	0.000119	0.000371	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000119	0.00037	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Methotrexate—multiple sclerosis	0.000119	0.00037	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000118	0.00037	CcSEcCtD
Cyclophosphamide—Convulsion—Betamethasone—multiple sclerosis	0.000118	0.000369	CcSEcCtD
Cyclophosphamide—Convulsion—Dexamethasone—multiple sclerosis	0.000118	0.000369	CcSEcCtD
Cyclophosphamide—Hypertension—Betamethasone—multiple sclerosis	0.000118	0.000368	CcSEcCtD
Cyclophosphamide—Hypertension—Dexamethasone—multiple sclerosis	0.000118	0.000368	CcSEcCtD
Cyclophosphamide—Asthenia—Mitoxantrone—multiple sclerosis	0.000117	0.000364	CcSEcCtD
Cyclophosphamide—CYP2A6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000117	0.0026	CbGpPWpGaD
Cyclophosphamide—Myalgia—Dexamethasone—multiple sclerosis	0.000116	0.000363	CcSEcCtD
Cyclophosphamide—Myalgia—Betamethasone—multiple sclerosis	0.000116	0.000363	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000116	0.00259	CbGpPWpGaD
Cyclophosphamide—Discomfort—Betamethasone—multiple sclerosis	0.000115	0.000358	CcSEcCtD
Cyclophosphamide—Discomfort—Dexamethasone—multiple sclerosis	0.000115	0.000358	CcSEcCtD
Cyclophosphamide—Haemoglobin—Methotrexate—multiple sclerosis	0.000115	0.000358	CcSEcCtD
Cyclophosphamide—Hypotension—Methylprednisolone—multiple sclerosis	0.000115	0.000357	CcSEcCtD
Cyclophosphamide—Pain—Prednisolone—multiple sclerosis	0.000114	0.000356	CcSEcCtD
Cyclophosphamide—Haemorrhage—Methotrexate—multiple sclerosis	0.000114	0.000356	CcSEcCtD
Cyclophosphamide—Hepatitis—Methotrexate—multiple sclerosis	0.000114	0.000356	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000113	0.00251	CbGpPWpGaD
Cyclophosphamide—Vision blurred—Prednisone—multiple sclerosis	0.000112	0.00035	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000112	0.000349	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000112	0.000348	CcSEcCtD
Cyclophosphamide—Oedema—Dexamethasone—multiple sclerosis	0.000111	0.000348	CcSEcCtD
Cyclophosphamide—Oedema—Betamethasone—multiple sclerosis	0.000111	0.000348	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000111	0.000348	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000111	0.000348	CcSEcCtD
Cyclophosphamide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000111	0.000347	CcSEcCtD
Cyclophosphamide—Infection—Dexamethasone—multiple sclerosis	0.000111	0.000345	CcSEcCtD
Cyclophosphamide—Infection—Betamethasone—multiple sclerosis	0.000111	0.000345	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Prednisone—multiple sclerosis	0.00011	0.000344	CcSEcCtD
Cyclophosphamide—Paraesthesia—Triamcinolone—multiple sclerosis	0.00011	0.000344	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Prednisolone—multiple sclerosis	0.00011	0.000343	CcSEcCtD
Cyclophosphamide—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00011	0.000343	CcSEcCtD
Cyclophosphamide—Visual impairment—Methotrexate—multiple sclerosis	0.00011	0.000343	CcSEcCtD
Cyclophosphamide—Anaemia—Prednisone—multiple sclerosis	0.00011	0.000343	CcSEcCtD
Cyclophosphamide—Shock—Dexamethasone—multiple sclerosis	0.00011	0.000342	CcSEcCtD
Cyclophosphamide—Shock—Betamethasone—multiple sclerosis	0.00011	0.000342	CcSEcCtD
Cyclophosphamide—Dyspnoea—Triamcinolone—multiple sclerosis	0.00011	0.000342	CcSEcCtD
Cyclophosphamide—Agitation—Prednisone—multiple sclerosis	0.000109	0.000341	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000109	0.00034	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000109	0.00034	CcSEcCtD
Cyclophosphamide—Tachycardia—Betamethasone—multiple sclerosis	0.000109	0.000339	CcSEcCtD
Cyclophosphamide—Tachycardia—Dexamethasone—multiple sclerosis	0.000109	0.000339	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Methotrexate—multiple sclerosis	0.000108	0.000337	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000108	0.00241	CbGpPWpGaD
Cyclophosphamide—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000108	0.000336	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000108	0.000336	CcSEcCtD
Cyclophosphamide—Malaise—Prednisone—multiple sclerosis	0.000107	0.000335	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000107	0.00239	CbGpPWpGaD
Cyclophosphamide—Tinnitus—Methotrexate—multiple sclerosis	0.000106	0.000332	CcSEcCtD
Cyclophosphamide—Anorexia—Dexamethasone—multiple sclerosis	0.000106	0.000331	CcSEcCtD
Cyclophosphamide—Anorexia—Betamethasone—multiple sclerosis	0.000106	0.000331	CcSEcCtD
Cyclophosphamide—Urticaria—Prednisolone—multiple sclerosis	0.000106	0.000331	CcSEcCtD
Cyclophosphamide—Fatigue—Triamcinolone—multiple sclerosis	0.000106	0.00033	CcSEcCtD
Cyclophosphamide—Fatigue—Methylprednisolone—multiple sclerosis	0.000106	0.00033	CcSEcCtD
Cyclophosphamide—Pain—Triamcinolone—multiple sclerosis	0.000105	0.000328	CcSEcCtD
Cyclophosphamide—Hypotension—Betamethasone—multiple sclerosis	0.000104	0.000325	CcSEcCtD
Cyclophosphamide—Hypotension—Dexamethasone—multiple sclerosis	0.000104	0.000325	CcSEcCtD
Cyclophosphamide—Vomiting—Mitoxantrone—multiple sclerosis	0.000104	0.000323	CcSEcCtD
Cyclophosphamide—CYP3A7—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000103	0.0023	CbGpPWpGaD
Cyclophosphamide—Convulsion—Prednisone—multiple sclerosis	0.000103	0.000321	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000103	0.00229	CbGpPWpGaD
Cyclophosphamide—Hypertension—Prednisone—multiple sclerosis	0.000103	0.00032	CcSEcCtD
Cyclophosphamide—Rash—Mitoxantrone—multiple sclerosis	0.000103	0.00032	CcSEcCtD
Cyclophosphamide—Dermatitis—Mitoxantrone—multiple sclerosis	0.000103	0.00032	CcSEcCtD
Cyclophosphamide—Chills—Methotrexate—multiple sclerosis	0.000102	0.00032	CcSEcCtD
Cyclophosphamide—Headache—Mitoxantrone—multiple sclerosis	0.000102	0.000318	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000102	0.000317	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000102	0.000317	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000101	0.00226	CbGpPWpGaD
Cyclophosphamide—Arthralgia—Prednisone—multiple sclerosis	0.000101	0.000316	CcSEcCtD
Cyclophosphamide—Myalgia—Prednisone—multiple sclerosis	0.000101	0.000316	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000101	0.000316	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000101	0.000315	CcSEcCtD
Cyclophosphamide—Alopecia—Methotrexate—multiple sclerosis	0.000101	0.000315	CcSEcCtD
Cyclophosphamide—Paraesthesia—Dexamethasone—multiple sclerosis	0.0001	0.000312	CcSEcCtD
Cyclophosphamide—Paraesthesia—Betamethasone—multiple sclerosis	0.0001	0.000312	CcSEcCtD
Cyclophosphamide—Discomfort—Prednisone—multiple sclerosis	0.0001	0.000312	CcSEcCtD
Cyclophosphamide—Erythema—Methotrexate—multiple sclerosis	9.94e-05	0.00031	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Prednisolone—multiple sclerosis	9.84e-05	0.000307	CcSEcCtD
Cyclophosphamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	9.8e-05	0.00219	CbGpPWpGaD
Cyclophosphamide—Urticaria—Triamcinolone—multiple sclerosis	9.76e-05	0.000304	CcSEcCtD
Cyclophosphamide—Urticaria—Methylprednisolone—multiple sclerosis	9.74e-05	0.000304	CcSEcCtD
Cyclophosphamide—Dysgeusia—Methotrexate—multiple sclerosis	9.73e-05	0.000304	CcSEcCtD
Cyclophosphamide—Body temperature increased—Triamcinolone—multiple sclerosis	9.71e-05	0.000303	CcSEcCtD
Cyclophosphamide—Oedema—Prednisone—multiple sclerosis	9.71e-05	0.000303	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Prednisone—multiple sclerosis	9.71e-05	0.000303	CcSEcCtD
Cyclophosphamide—Decreased appetite—Dexamethasone—multiple sclerosis	9.69e-05	0.000302	CcSEcCtD
Cyclophosphamide—Decreased appetite—Betamethasone—multiple sclerosis	9.69e-05	0.000302	CcSEcCtD
Cyclophosphamide—Nausea—Mitoxantrone—multiple sclerosis	9.67e-05	0.000302	CcSEcCtD
Cyclophosphamide—Infection—Prednisone—multiple sclerosis	9.64e-05	0.000301	CcSEcCtD
Cyclophosphamide—Fatigue—Dexamethasone—multiple sclerosis	9.61e-05	0.0003	CcSEcCtD
Cyclophosphamide—Fatigue—Betamethasone—multiple sclerosis	9.61e-05	0.0003	CcSEcCtD
Cyclophosphamide—Shock—Prednisone—multiple sclerosis	9.55e-05	0.000298	CcSEcCtD
Cyclophosphamide—Pain—Betamethasone—multiple sclerosis	9.53e-05	0.000297	CcSEcCtD
Cyclophosphamide—Pain—Dexamethasone—multiple sclerosis	9.53e-05	0.000297	CcSEcCtD
Cyclophosphamide—Tachycardia—Prednisone—multiple sclerosis	9.47e-05	0.000295	CcSEcCtD
Cyclophosphamide—CYP2A6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	9.45e-05	0.00211	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.41e-05	0.0021	CbGpPWpGaD
Cyclophosphamide—Hyperhidrosis—Prednisone—multiple sclerosis	9.38e-05	0.000293	CcSEcCtD
Cyclophosphamide—Vision blurred—Methotrexate—multiple sclerosis	9.37e-05	0.000292	CcSEcCtD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	9.26e-05	0.00207	CbGpPWpGaD
Cyclophosphamide—Anorexia—Prednisone—multiple sclerosis	9.25e-05	0.000289	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Methotrexate—multiple sclerosis	9.22e-05	0.000288	CcSEcCtD
Cyclophosphamide—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	9.2e-05	0.00205	CbGpPWpGaD
Cyclophosphamide—Anaemia—Methotrexate—multiple sclerosis	9.19e-05	0.000287	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Betamethasone—multiple sclerosis	9.18e-05	0.000286	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Dexamethasone—multiple sclerosis	9.18e-05	0.000286	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Triamcinolone—multiple sclerosis	9.05e-05	0.000282	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Methylprednisolone—multiple sclerosis	9.03e-05	0.000282	CcSEcCtD
Cyclophosphamide—Malaise—Methotrexate—multiple sclerosis	8.96e-05	0.00028	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	8.92e-05	0.00199	CbGpPWpGaD
Cyclophosphamide—Leukopenia—Methotrexate—multiple sclerosis	8.9e-05	0.000277	CcSEcCtD
Cyclophosphamide—CYP2C18—Metabolism—SRM—multiple sclerosis	8.89e-05	0.00199	CbGpPWpGaD
Cyclophosphamide—Urticaria—Betamethasone—multiple sclerosis	8.85e-05	0.000276	CcSEcCtD
Cyclophosphamide—Urticaria—Dexamethasone—multiple sclerosis	8.85e-05	0.000276	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	8.84e-05	0.000276	CcSEcCtD
Cyclophosphamide—Dizziness—Prednisolone—multiple sclerosis	8.83e-05	0.000275	CcSEcCtD
Cyclophosphamide—Asthenia—Triamcinolone—multiple sclerosis	8.81e-05	0.000275	CcSEcCtD
Cyclophosphamide—Body temperature increased—Dexamethasone—multiple sclerosis	8.81e-05	0.000275	CcSEcCtD
Cyclophosphamide—Body temperature increased—Betamethasone—multiple sclerosis	8.81e-05	0.000275	CcSEcCtD
Cyclophosphamide—Asthenia—Methylprednisolone—multiple sclerosis	8.79e-05	0.000274	CcSEcCtD
Cyclophosphamide—Paraesthesia—Prednisone—multiple sclerosis	8.71e-05	0.000272	CcSEcCtD
Cyclophosphamide—Pruritus—Triamcinolone—multiple sclerosis	8.69e-05	0.000271	CcSEcCtD
Cyclophosphamide—Cough—Methotrexate—multiple sclerosis	8.67e-05	0.000271	CcSEcCtD
Cyclophosphamide—Pruritus—Methylprednisolone—multiple sclerosis	8.67e-05	0.00027	CcSEcCtD
Cyclophosphamide—Convulsion—Methotrexate—multiple sclerosis	8.61e-05	0.000269	CcSEcCtD
Cyclophosphamide—Myalgia—Methotrexate—multiple sclerosis	8.46e-05	0.000264	CcSEcCtD
Cyclophosphamide—Arthralgia—Methotrexate—multiple sclerosis	8.46e-05	0.000264	CcSEcCtD
Cyclophosphamide—Chest pain—Methotrexate—multiple sclerosis	8.46e-05	0.000264	CcSEcCtD
Cyclophosphamide—Decreased appetite—Prednisone—multiple sclerosis	8.44e-05	0.000263	CcSEcCtD
Cyclophosphamide—Rash—Prednisolone—multiple sclerosis	8.42e-05	0.000263	CcSEcCtD
Cyclophosphamide—Dermatitis—Prednisolone—multiple sclerosis	8.41e-05	0.000262	CcSEcCtD
Cyclophosphamide—Diarrhoea—Methylprednisolone—multiple sclerosis	8.38e-05	0.000262	CcSEcCtD
Cyclophosphamide—Fatigue—Prednisone—multiple sclerosis	8.37e-05	0.000261	CcSEcCtD
Cyclophosphamide—Headache—Prednisolone—multiple sclerosis	8.37e-05	0.000261	CcSEcCtD
Cyclophosphamide—Discomfort—Methotrexate—multiple sclerosis	8.36e-05	0.000261	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	8.34e-05	0.00186	CbGpPWpGaD
Cyclophosphamide—Constipation—Prednisone—multiple sclerosis	8.3e-05	0.000259	CcSEcCtD
Cyclophosphamide—CYP2C18—Biological oxidations—POMC—multiple sclerosis	8.24e-05	0.00184	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	8.19e-05	0.00183	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	8.19e-05	0.00183	CbGpPWpGaD
Cyclophosphamide—Confusional state—Methotrexate—multiple sclerosis	8.18e-05	0.000255	CcSEcCtD
Cyclophosphamide—Dizziness—Triamcinolone—multiple sclerosis	8.12e-05	0.000253	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Methotrexate—multiple sclerosis	8.11e-05	0.000253	CcSEcCtD
Cyclophosphamide—Dizziness—Methylprednisolone—multiple sclerosis	8.1e-05	0.000253	CcSEcCtD
Cyclophosphamide—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	8.07e-05	0.0018	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	8.07e-05	0.0018	CbGpPWpGaD
Cyclophosphamide—Infection—Methotrexate—multiple sclerosis	8.06e-05	0.000251	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—CD86—multiple sclerosis	8.03e-05	0.00179	CbGpPWpGaD
Cyclophosphamide—Feeling abnormal—Prednisone—multiple sclerosis	8e-05	0.000249	CcSEcCtD
Cyclophosphamide—Asthenia—Betamethasone—multiple sclerosis	8e-05	0.000249	CcSEcCtD
Cyclophosphamide—Asthenia—Dexamethasone—multiple sclerosis	8e-05	0.000249	CcSEcCtD
Cyclophosphamide—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.97e-05	0.00178	CbGpPWpGaD
Cyclophosphamide—Thrombocytopenia—Methotrexate—multiple sclerosis	7.94e-05	0.000248	CcSEcCtD
Cyclophosphamide—Nausea—Prednisolone—multiple sclerosis	7.93e-05	0.000247	CcSEcCtD
Cyclophosphamide—Pruritus—Dexamethasone—multiple sclerosis	7.88e-05	0.000246	CcSEcCtD
Cyclophosphamide—Pruritus—Betamethasone—multiple sclerosis	7.88e-05	0.000246	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	7.88e-05	0.00176	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—IL10—multiple sclerosis	7.88e-05	0.00176	CbGpPWpGaD
Cyclophosphamide—Hyperhidrosis—Methotrexate—multiple sclerosis	7.84e-05	0.000245	CcSEcCtD
Cyclophosphamide—Vomiting—Triamcinolone—multiple sclerosis	7.81e-05	0.000244	CcSEcCtD
Cyclophosphamide—Vomiting—Methylprednisolone—multiple sclerosis	7.79e-05	0.000243	CcSEcCtD
Cyclophosphamide—Rash—Triamcinolone—multiple sclerosis	7.74e-05	0.000242	CcSEcCtD
Cyclophosphamide—Dermatitis—Triamcinolone—multiple sclerosis	7.74e-05	0.000241	CcSEcCtD
Cyclophosphamide—Anorexia—Methotrexate—multiple sclerosis	7.73e-05	0.000241	CcSEcCtD
Cyclophosphamide—Rash—Methylprednisolone—multiple sclerosis	7.73e-05	0.000241	CcSEcCtD
Cyclophosphamide—Dermatitis—Methylprednisolone—multiple sclerosis	7.72e-05	0.000241	CcSEcCtD
Cyclophosphamide—Urticaria—Prednisone—multiple sclerosis	7.71e-05	0.00024	CcSEcCtD
Cyclophosphamide—Headache—Triamcinolone—multiple sclerosis	7.69e-05	0.00024	CcSEcCtD
Cyclophosphamide—Headache—Methylprednisolone—multiple sclerosis	7.68e-05	0.000239	CcSEcCtD
Cyclophosphamide—Body temperature increased—Prednisone—multiple sclerosis	7.67e-05	0.000239	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—IL4—multiple sclerosis	7.66e-05	0.00171	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.63e-05	0.0017	CbGpPWpGaD
Cyclophosphamide—Diarrhoea—Dexamethasone—multiple sclerosis	7.63e-05	0.000238	CcSEcCtD
Cyclophosphamide—Diarrhoea—Betamethasone—multiple sclerosis	7.63e-05	0.000238	CcSEcCtD
Cyclophosphamide—Hypotension—Methotrexate—multiple sclerosis	7.58e-05	0.000236	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	7.49e-05	0.00167	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.46e-05	0.00166	CbGpPWpGaD
Cyclophosphamide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	7.39e-05	0.000231	CcSEcCtD
Cyclophosphamide—Dizziness—Betamethasone—multiple sclerosis	7.37e-05	0.00023	CcSEcCtD
Cyclophosphamide—Dizziness—Dexamethasone—multiple sclerosis	7.37e-05	0.00023	CcSEcCtD
Cyclophosphamide—Nausea—Triamcinolone—multiple sclerosis	7.3e-05	0.000228	CcSEcCtD
Cyclophosphamide—Paraesthesia—Methotrexate—multiple sclerosis	7.28e-05	0.000227	CcSEcCtD
Cyclophosphamide—Nausea—Methylprednisolone—multiple sclerosis	7.28e-05	0.000227	CcSEcCtD
Cyclophosphamide—Dyspnoea—Methotrexate—multiple sclerosis	7.23e-05	0.000226	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Prednisone—multiple sclerosis	7.15e-05	0.000223	CcSEcCtD
Cyclophosphamide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.11e-05	0.00159	CbGpPWpGaD
Cyclophosphamide—Vomiting—Dexamethasone—multiple sclerosis	7.09e-05	0.000221	CcSEcCtD
Cyclophosphamide—Vomiting—Betamethasone—multiple sclerosis	7.09e-05	0.000221	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—FAS—multiple sclerosis	7.06e-05	0.00158	CbGpPWpGaD
Cyclophosphamide—Decreased appetite—Methotrexate—multiple sclerosis	7.05e-05	0.00022	CcSEcCtD
Cyclophosphamide—Rash—Betamethasone—multiple sclerosis	7.03e-05	0.000219	CcSEcCtD
Cyclophosphamide—Rash—Dexamethasone—multiple sclerosis	7.03e-05	0.000219	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	7.02e-05	0.00157	CbGpPWpGaD
Cyclophosphamide—Dermatitis—Dexamethasone—multiple sclerosis	7.02e-05	0.000219	CcSEcCtD
Cyclophosphamide—Dermatitis—Betamethasone—multiple sclerosis	7.02e-05	0.000219	CcSEcCtD
Cyclophosphamide—Fatigue—Methotrexate—multiple sclerosis	6.99e-05	0.000218	CcSEcCtD
Cyclophosphamide—Headache—Betamethasone—multiple sclerosis	6.98e-05	0.000218	CcSEcCtD
Cyclophosphamide—Headache—Dexamethasone—multiple sclerosis	6.98e-05	0.000218	CcSEcCtD
Cyclophosphamide—Asthenia—Prednisone—multiple sclerosis	6.96e-05	0.000217	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	6.94e-05	0.00155	CbGpPWpGaD
Cyclophosphamide—Pain—Methotrexate—multiple sclerosis	6.94e-05	0.000216	CcSEcCtD
Cyclophosphamide—Pruritus—Prednisone—multiple sclerosis	6.87e-05	0.000214	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Methotrexate—multiple sclerosis	6.68e-05	0.000208	CcSEcCtD
Cyclophosphamide—Diarrhoea—Prednisone—multiple sclerosis	6.64e-05	0.000207	CcSEcCtD
Cyclophosphamide—Nausea—Betamethasone—multiple sclerosis	6.62e-05	0.000206	CcSEcCtD
Cyclophosphamide—Nausea—Dexamethasone—multiple sclerosis	6.62e-05	0.000206	CcSEcCtD
Cyclophosphamide—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.54e-05	0.00146	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.48e-05	0.00145	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.46e-05	0.00144	CbGpPWpGaD
Cyclophosphamide—Urticaria—Methotrexate—multiple sclerosis	6.44e-05	0.000201	CcSEcCtD
Cyclophosphamide—Dizziness—Prednisone—multiple sclerosis	6.42e-05	0.0002	CcSEcCtD
Cyclophosphamide—Body temperature increased—Methotrexate—multiple sclerosis	6.41e-05	0.0002	CcSEcCtD
Cyclophosphamide—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	6.34e-05	0.00142	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—CYP24A1—multiple sclerosis	6.27e-05	0.0014	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—CYP27B1—multiple sclerosis	6.27e-05	0.0014	CbGpPWpGaD
Cyclophosphamide—Vomiting—Prednisone—multiple sclerosis	6.17e-05	0.000192	CcSEcCtD
Cyclophosphamide—Rash—Prednisone—multiple sclerosis	6.12e-05	0.000191	CcSEcCtD
Cyclophosphamide—Dermatitis—Prednisone—multiple sclerosis	6.11e-05	0.000191	CcSEcCtD
Cyclophosphamide—Headache—Prednisone—multiple sclerosis	6.08e-05	0.00019	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Methotrexate—multiple sclerosis	5.98e-05	0.000186	CcSEcCtD
Cyclophosphamide—CYP3A7—Metabolism—SRM—multiple sclerosis	5.91e-05	0.00132	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—CD80—multiple sclerosis	5.86e-05	0.00131	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.86e-05	0.00131	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.86e-05	0.00131	CbGpPWpGaD
Cyclophosphamide—Asthenia—Methotrexate—multiple sclerosis	5.82e-05	0.000182	CcSEcCtD
Cyclophosphamide—Nausea—Prednisone—multiple sclerosis	5.76e-05	0.00018	CcSEcCtD
Cyclophosphamide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.76e-05	0.00129	CbGpPWpGaD
Cyclophosphamide—Pruritus—Methotrexate—multiple sclerosis	5.74e-05	0.000179	CcSEcCtD
Cyclophosphamide—CYP2C18—Metabolism—GPC5—multiple sclerosis	5.73e-05	0.00128	CbGpPWpGaD
Cyclophosphamide—Diarrhoea—Methotrexate—multiple sclerosis	5.55e-05	0.000173	CcSEcCtD
Cyclophosphamide—CYP3A7—Biological oxidations—POMC—multiple sclerosis	5.48e-05	0.00122	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—SRM—multiple sclerosis	5.42e-05	0.00121	CbGpPWpGaD
Cyclophosphamide—Dizziness—Methotrexate—multiple sclerosis	5.36e-05	0.000167	CcSEcCtD
Cyclophosphamide—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.3e-05	0.00118	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.26e-05	0.00117	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.23e-05	0.00117	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.23e-05	0.00117	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	5.22e-05	0.00116	CbGpPWpGaD
Cyclophosphamide—Vomiting—Methotrexate—multiple sclerosis	5.16e-05	0.000161	CcSEcCtD
Cyclophosphamide—Rash—Methotrexate—multiple sclerosis	5.11e-05	0.00016	CcSEcCtD
Cyclophosphamide—Dermatitis—Methotrexate—multiple sclerosis	5.11e-05	0.000159	CcSEcCtD
Cyclophosphamide—Headache—Methotrexate—multiple sclerosis	5.08e-05	0.000158	CcSEcCtD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	5.07e-05	0.00113	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Biological oxidations—POMC—multiple sclerosis	5.02e-05	0.00112	CbGpPWpGaD
Cyclophosphamide—Nausea—Methotrexate—multiple sclerosis	4.82e-05	0.00015	CcSEcCtD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.77e-05	0.00106	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.77e-05	0.00106	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—RRM1—multiple sclerosis	4.75e-05	0.00106	CbGpPWpGaD
Cyclophosphamide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	4.72e-05	0.00105	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	4.63e-05	0.00103	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—SRM—multiple sclerosis	4.37e-05	0.000976	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.28e-05	0.000955	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—SRM—multiple sclerosis	4.27e-05	0.000954	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	4.17e-05	0.00093	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	4.17e-05	0.00093	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	4.13e-05	0.000923	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—IL2—multiple sclerosis	4.12e-05	0.000919	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	4.07e-05	0.000909	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Biological oxidations—POMC—multiple sclerosis	4.05e-05	0.000905	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Biological oxidations—POMC—multiple sclerosis	3.96e-05	0.000884	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	3.95e-05	0.000883	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—CYP27B1—multiple sclerosis	3.82e-05	0.000852	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—CYP24A1—multiple sclerosis	3.82e-05	0.000852	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—GPC5—multiple sclerosis	3.81e-05	0.00085	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—SRM—multiple sclerosis	3.7e-05	0.000826	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—GPC5—multiple sclerosis	3.49e-05	0.00078	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	3.49e-05	0.000778	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.47e-05	0.000774	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Biological oxidations—POMC—multiple sclerosis	3.43e-05	0.000766	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—SRM—multiple sclerosis	3.3e-05	0.000738	CbGpPWpGaD
Cyclophosphamide—CYP2A6—NRF2 pathway—TGFB1—multiple sclerosis	3.3e-05	0.000737	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—SRM—multiple sclerosis	3.22e-05	0.00072	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	3.21e-05	0.000717	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—RRM1—multiple sclerosis	3.16e-05	0.000705	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.13e-05	0.000698	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CYP24A1—multiple sclerosis	3.08e-05	0.000688	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—CYP27B1—multiple sclerosis	3.08e-05	0.000688	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Biological oxidations—POMC—multiple sclerosis	3.06e-05	0.000684	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—SRM—multiple sclerosis	3.04e-05	0.000678	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—SRM—multiple sclerosis	3.01e-05	0.000673	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	3.01e-05	0.000672	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	3.01e-05	0.000672	CbGpPWpGaD
Cyclophosphamide—ABCB1—Allograft Rejection—TNF—multiple sclerosis	3e-05	0.000669	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—RRM1—multiple sclerosis	2.89e-05	0.000646	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—GPC5—multiple sclerosis	2.82e-05	0.000629	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.82e-05	0.000629	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Biological oxidations—POMC—multiple sclerosis	2.79e-05	0.000623	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.76e-05	0.000617	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—GPC5—multiple sclerosis	2.75e-05	0.000615	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—BCHE—multiple sclerosis	2.73e-05	0.000609	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	2.61e-05	0.000582	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	2.61e-05	0.000582	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.55e-05	0.000569	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—GPC5—multiple sclerosis	2.39e-05	0.000532	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—RRM1—multiple sclerosis	2.33e-05	0.000521	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.33e-05	0.00052	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.33e-05	0.00052	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—RRM1—multiple sclerosis	2.28e-05	0.000509	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.28e-05	0.000508	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.27e-05	0.000507	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.27e-05	0.000507	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.14e-05	0.000478	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.14e-05	0.000478	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.13e-05	0.000475	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.12e-05	0.000474	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.12e-05	0.000474	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—GPC5—multiple sclerosis	2.08e-05	0.000464	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.07e-05	0.000463	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—SRM—multiple sclerosis	1.99e-05	0.000444	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—RRM1—multiple sclerosis	1.98e-05	0.000441	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.96e-05	0.000437	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.94e-05	0.000433	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.84e-05	0.000411	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—BCHE—multiple sclerosis	1.81e-05	0.000405	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.76e-05	0.000394	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—RRM1—multiple sclerosis	1.72e-05	0.000384	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—BCHE—multiple sclerosis	1.66e-05	0.000371	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—APOE—multiple sclerosis	1.64e-05	0.000366	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.62e-05	0.000362	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.61e-05	0.000359	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.59e-05	0.000355	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.58e-05	0.000354	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.55e-05	0.000347	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.53e-05	0.000342	CbGpPWpGaD
Cyclophosphamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.48e-05	0.00033	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—POMC—multiple sclerosis	1.41e-05	0.000315	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.4e-05	0.000312	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.4e-05	0.000312	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.37e-05	0.000306	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—BCHE—multiple sclerosis	1.34e-05	0.000299	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.32e-05	0.000294	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.31e-05	0.000293	CbGpPWpGaD
Cyclophosphamide—CYP2C18—Metabolism—ALB—multiple sclerosis	1.28e-05	0.000287	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.28e-05	0.000286	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.25e-05	0.000279	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.2e-05	0.000268	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.18e-05	0.000262	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.14e-05	0.000253	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—APOE—multiple sclerosis	1.09e-05	0.000243	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.07e-05	0.000239	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.07e-05	0.000239	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.06e-05	0.000237	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.01e-05	0.000226	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—APOE—multiple sclerosis	1e-05	0.000223	CbGpPWpGaD
Cyclophosphamide—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.95e-06	0.000222	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—BCHE—multiple sclerosis	9.89e-06	0.000221	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.77e-06	0.000218	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—POMC—multiple sclerosis	9.37e-06	0.000209	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—BCHE—multiple sclerosis	9.32e-06	0.000208	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—BCHE—multiple sclerosis	9.24e-06	0.000206	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—POMC—multiple sclerosis	8.59e-06	0.000192	CbGpPWpGaD
Cyclophosphamide—CYP3A7—Metabolism—ALB—multiple sclerosis	8.54e-06	0.000191	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—APOE—multiple sclerosis	8.07e-06	0.00018	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—APOE—multiple sclerosis	7.88e-06	0.000176	CbGpPWpGaD
Cyclophosphamide—CYP2A6—Metabolism—ALB—multiple sclerosis	7.83e-06	0.000175	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—POMC—multiple sclerosis	6.93e-06	0.000155	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—APOE—multiple sclerosis	6.83e-06	0.000152	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—POMC—multiple sclerosis	6.77e-06	0.000151	CbGpPWpGaD
Cyclophosphamide—CYP2B6—Metabolism—ALB—multiple sclerosis	6.32e-06	0.000141	CbGpPWpGaD
Cyclophosphamide—CYP3A5—Metabolism—ALB—multiple sclerosis	6.17e-06	0.000138	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—APOE—multiple sclerosis	6.1e-06	0.000136	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—BCHE—multiple sclerosis	6.09e-06	0.000136	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—APOE—multiple sclerosis	5.95e-06	0.000133	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—POMC—multiple sclerosis	5.87e-06	0.000131	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—APOE—multiple sclerosis	5.61e-06	0.000125	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—APOE—multiple sclerosis	5.56e-06	0.000124	CbGpPWpGaD
Cyclophosphamide—CYP2C8—Metabolism—ALB—multiple sclerosis	5.35e-06	0.000119	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—POMC—multiple sclerosis	5.24e-06	0.000117	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—POMC—multiple sclerosis	5.11e-06	0.000114	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—POMC—multiple sclerosis	4.82e-06	0.000108	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—POMC—multiple sclerosis	4.77e-06	0.000107	CbGpPWpGaD
Cyclophosphamide—CYP2C19—Metabolism—ALB—multiple sclerosis	4.77e-06	0.000107	CbGpPWpGaD
Cyclophosphamide—ABCB1—Metabolism—ALB—multiple sclerosis	4.66e-06	0.000104	CbGpPWpGaD
Cyclophosphamide—CYP2D6—Metabolism—ALB—multiple sclerosis	4.39e-06	9.8e-05	CbGpPWpGaD
Cyclophosphamide—CYP2C9—Metabolism—ALB—multiple sclerosis	4.35e-06	9.72e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—APOE—multiple sclerosis	3.67e-06	8.18e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—POMC—multiple sclerosis	3.15e-06	7.03e-05	CbGpPWpGaD
Cyclophosphamide—CYP3A4—Metabolism—ALB—multiple sclerosis	2.87e-06	6.41e-05	CbGpPWpGaD
